The introduction of sodium-glucose cotransporter-2-inhibitors (SGLT2i) has positively affected the outcomes of patients suffering from type 2 diabetes (T2D) [1,2], chronic kidney disease (CKD) [3], and congestive heart failure (CHF) [4,5]. This evidence concerns the gene SLC5A2 and congestive heart failure.